A Phase 2 interventional study of Bimekizumab and Placebo in Chronic Plaque Psoriasis, sponsored by UCB Biopharma SRL. Completed at 36 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-10-18.
Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing bimekizumab in Psoriasis — 4 open to participants now, 5 under way, 3 of them phase 3. bimekizumab · Psoriasis.
Among the 20 studies testing bimekizumab in Psoriasis, this one is the 8th largest by enrollment, is one of 3 that started in 2016, is one of 6 in phase 2, and was the 3rd registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →4 of the 20 studies testing bimekizumab in Psoriasis are open now, in 12 countries. Recruiting first, the newest first:
UCB Biopharma SRL · Sites in United States, Canada, China and 10 more countries
Ages 18+
Centre Hospitalier Universitaire de Nice · Sites in France
Ages 18–45
University Hospital, Rouen · Sites in France
Ages 18–60
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
bimekizumab: first FDA approval 2023 (BIMZELX), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 3 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 217 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 161 across the 20 interventional studies. Of the 15 that completed or were terminated, 12 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 20 have an industry lead sponsor. The 8 most frequent:
This study is registered under UCB Biopharma SRL, one of the names counted as UCB S.A.. Under that name alone:
UCB Biopharma SRL is the lead sponsor of 130 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 50 (70%) have results posted.
26 studies in Psoriasis by UCB S.A.: 1 open now, 2 under way, 2 of them phase 3. Of 24 finished, 19 (79%) have results posted.
Among the 26 studies in Psoriasis by UCB S.A., this one is the 11th largest by enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2016, is one of 7 in phase 2, and was the 9th registered.
UCB S.A.’s Psoriasis studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 20 studies testing bimekizumab in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among UCB S.A.’s 26 in Psoriasis:
This tab as a report to print or save as PDF → With an account.
This is a multicenter extension study to assess the long-term safety, tolerability and efficacy of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects with a PASI90 response at Week 12 and receiving Placebo in PS0010 entering PS0011 will receive Placebo.
Other: Placebo
Subjects with a PASI90 response at Week 12 receiving dosing regimen 1 in PS0010 entering PS0011 will receive the same dosing regimen. Subjects who do not achieve PASI90 response at Week 12 receiving dosing regimen 1 in PS0010 will be assigned to a higher dosing regimen.
Drug: Bimekizumab
Subjects with a PASI90 response at Week 12 receiving dosing regimen 2 in PS0010 entering PS0011 will receive the same dosing regimen. Subjects who do not achieve PASI90 response at Week 12 receiving dosing regimen 2 in PS0010 will be assigned to a higher dosing regimen.
Drug: Bimekizumab
Subjects that were initially randomized to bimekizumab dosage regimen 3, 4 and 5 in PS0010 will receive bimekizumab dosing regimen 3.
Drug: Bimekizumab
Subjects will receive bimekizumab injections every four weeks (Q4W)
Also known as: UCB4940
Subjects will receive Placebo injections every four weeks (Q4W)
Incidence of Treatment Emergent Adverse Events (TEAEs) Adjusted by Duration of Subject Exposure to Treatment
Treatment-emergent Adverse Events (TEAEs) were defined as those events which started on or after the date of first dose of PS0011 investigational medicinal product (IMP), or events in which severity worsened on or after the date of first dose of PS0011 study medication. The exposure adjusted incidence rate (EAIR) is defined as the number of subjects (n) with a specific AE adjusted for the exposure and was scaled to 100 subject-years: where the numerator is the total number of subjects experiencing the AE and the denominator is the total time at risk scaled to 100 subject-years; that is, the total summation of individual subject-years at risk up to the first occurrence of the AE for subjects with that AE, and the total subject-years at risk for those subjects not experiencing that AE, divided by 100.
Time frame: From Baseline until Safety Follow-Up Visit (up to Week 64)
Percentage of Participants With Psoriasis Area Severity Index (PASI90) Response Over Time
The PASI90 response assessments are based on at least 90% improvement in the PASI score from Baseline. It averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale) and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). The PASI score ranges from 0 to 72 with a higher score indicating increased disease severity. PASI90 response is defined to be equal to 1 if the percentage improvement from Baseline in the PASI scores is 90% or greater and 0 if the percentage improvement from Baseline is less than 90%. This Outcome Measure presents results relative to PS0010 Baseline starting at PS0011 Baseline by PS0010 Week 12 response status.
Time frame: From Baseline during the Treatment Period (up to Week 48)
Percentage of Participants With Investigator´s Global Assessment Response (Clear or Almost Clear With at Least a 2 Category Improvement From Baseline on a 5-point Scale) Over Time
The Investigator's Global Assessment (IGA) measures the overall severity following a 5-point scale (0-4), where scale 0= clear, no signs of psoriasis; presence of post-inflammatory hyperpigmentation, scale 1= almost clear, no thickening; normal to pink coloration; no to minimal focal scaling, scale 2= mild thickening, pink to light red coloration and predominately fine scaling, 3= moderate, clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable to moderate thickening; moderate scaling and 4= severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions. IGA response is defined as clear (0) or almost clear (1) with at least a two category improvement from Baseline. This Outcome Measure presents results relative to PS0010 Baseline starting at PS0011 Baseline by PS0010 Week 12 response status.
Time frame: From Baseline during the Treatment Period (up to Week 48)
The study started to enroll participants in December 2016 and concluded in September 2018. Among the 217 participants in PS0011, no participants were assigned to receive placebo.
| Milestone | Bimekizumab 64 mg Q4W | Bimekizumab 160 mg Q4W | Bimekizumab 320 mg Q4W |
|---|---|---|---|
| Started | 15 | 111 | 91 |
| Completed | 15 | 92 | 75 |
| Not completed | 0 | 19 | 16 |
| Withdrew: Death | 0 | 0 | 1 |
| Withdrew: Adverse event | 0 | 4 | 2 |
| Withdrew: Protocol violation | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 2 | 1 |
| Withdrew: Withdrawal by subject | 0 | 3 | 4 |
| Withdrew: Withdrawal criteria #9 | 0 | 4 | 6 |
| Withdrew: Withdrawal criteria #12 | 0 | 4 | 2 |
| Withdrew: Pdili and withdrawal criteria #9 | 0 | 1 | 0 |
Treatment-emergent Adverse Events (TEAEs) were defined as those events which started on or after the date of first dose of PS0011 investigational medicinal product (IMP), or events in which severity worsened on or after the date of first dose of PS0011 study medication. The exposure adjusted incidence rate (EAIR) is defined as the number of subjects (n) with a specific AE adjusted for the exposure and was scaled to 100 subject-years: where the numerator is the total number of subjects experiencing the AE and the denominator is the total time at risk scaled to 100 subject-years; that is, the total summation of individual subject-years at risk up to the first occurrence of the AE for subjects with that AE, and the total subject-years at risk for those subjects not experiencing that AE, divided by 100.
| no. of new events per 100 subject-years | Bimekizumab 64 mg Q4W (SS) | Bimekizumab 160 mg Q4W (SS) | Bimekizumab 320 mg Q4W (SS) |
|---|---|---|---|
| Incidence of Treatment Emergent Adverse Events (TEAEs) Adjusted by Duration of Subject Exposure to Treatment | 110.68 (53.08 to 203.55) | 225.26 (182.88 to 274.53) | 206.82 (162.95 to 258.86) |
The PASI90 response assessments are based on at least 90% improvement in the PASI score from Baseline. It averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale) and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). The PASI score ranges from 0 to 72 with a higher score indicating increased disease severity. PASI90 response is defined to be equal to 1 if the percentage improvement from Baseline in the PASI scores is 90% or greater and 0 if the percentage improvement from Baseline is less than 90%. This Outcome Measure presents results relative to PS0010 Baseline starting at PS0011 Baseline by PS0010 Week 12 response status.
| percentage of participants | Bimekizumab 64 mg Q4W/Bimekizumab 64 mg Q4W/R (FAS) | Bimekizumab 160 mg Q4W/Bimekizumab 160 mg Q4W/R (FAS) | Bimekizumab 320 mg Q4W/Bimekizumab 320 mg Q4W/R (FAS) | Bimekizumab 480 mg Q4W/Bimekizumab 320 mg Q4W/R (FAS) | Placebo/Bimekizumab 160 mg Q4W/NR (FAS) | Bimekizumab 64 mg Q4W/Bimekizumab 160 mg Q4W/NR (FAS) | Bimekizumab 160 mg Q4W/Bimekizumab 320 mg Q4W/NR (FAS) | Bimekizumab 320 mg Q4W/Bimekizumab 320 mg Q4W/NR (FAS) | Bimekizumab 480 mg Q4W/Bimekizumab 320 mg Q4W/NR (FAS) |
|---|---|---|---|---|---|---|---|---|---|
| PS0011 Baseline | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 |
| Week 4 | 100 | 100 | 97.0 | 100 | 45.9 | 42.1 | 42.9 | 66.7 | 50.0 |
| Week 8 | 100 | 96.4 | 100 | 100 | 67.6 | 73.7 | 57.1 | 83.3 | 50.0 |
| Week 12 | 100 | 96.4 | 100 | 96.7 | 81.1 | 78.9 | 64.3 | 100 | 62.5 |
| Week 16 | 100 | 92.7 | 100 | 96.7 | 83.8 | 78.9 | 64.3 | 100 | 62.5 |
| Week 20 | 100 | 89.1 | 93.9 | 96.7 | 89.2 | 84.2 | 78.6 | 83.3 | 62.5 |
| Week 24 | 100 | 85.5 | 97.0 | 96.7 | 83.8 | 78.9 | 71.4 | 83.3 | 75.0 |
| Week 28 | 93.3 | 90.9 | 97.0 | 96.7 | 91.9 | 84.2 | 71.4 | 83.3 | 50.0 |
| Week 32 | 100 | 89.1 | 97.0 | 93.3 | 91.9 | 73.7 | 71.4 | 83.3 | 50.0 |
| Week 36 | 100 | 85.5 | 97.0 | 93.3 | 91.9 | 73.7 | 71.4 | 66.7 | 50.0 |
| Week 40 | 100 | 83.6 | 87.9 | 86.7 | 89.2 | 78.9 | 71.4 | 83.3 | 50.0 |
| Week 44 | 100 | 81.8 | 87.9 | 86.7 | 89.2 | 78.9 | 71.4 | 83.3 | 50.0 |
| Week 48 | 100 | 80.0 | 87.9 | 86.7 | 91.9 | 68.4 | 71.4 | 66.7 | 50.0 |
The Investigator's Global Assessment (IGA) measures the overall severity following a 5-point scale (0-4), where scale 0= clear, no signs of psoriasis; presence of post-inflammatory hyperpigmentation, scale 1= almost clear, no thickening; normal to pink coloration; no to minimal focal scaling, scale 2= mild thickening, pink to light red coloration and predominately fine scaling, 3= moderate, clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable to moderate thickening; moderate scaling and 4= severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions. IGA response is defined as clear (0) or almost clear (1) with at least a two category improvement from Baseline. This Outcome Measure presents results relative to PS0010 Baseline starting at PS0011 Baseline by PS0010 Week 12 response status.
| percentage of participants | Bimekizumab 64 mg Q4W/Bimekizumab 64 mg Q4W/R (FAS) | Bimekizumab 160 mg Q4W/Bimekizumab 160 mg Q4W/R (FAS) | Bimekizumab 320 mg Q4W/Bimekizumab 320 mg Q4W/R (FAS) | Bimekizumab 480 mg Q4W/Bimekizumab 320 mg Q4W/R (FAS) | Placebo/Bimekizumab 160 mg Q4W/NR (FAS) | Bimekizumab 64 mg Q4W/Bimekizumab 160 mg Q4W/NR (FAS) | Bimekizumab 160 mg Q4W/Bimekizumab 320 mg Q4W/NR (FAS) | Bimekizumab 320 mg Q4W/Bimekizumab 320 mg Q4W/NR (FAS) | Bimekizumab 480 mg Q4W/Bimekizumab 320 mg Q4W/NR (FAS) |
|---|---|---|---|---|---|---|---|---|---|
| PS0011 Baseline | 100 | 96.4 | 100 | 100 | 5.4 | 10.5 | 35.7 | 50.0 | 25.0 |
| Week 4 | 100 | 98.2 | 97.0 | 100 | 56.8 | 57.9 | 42.9 | 66.7 | 62.5 |
| Week 8 | 100 | 96.4 | 97.0 | 100 | 75.7 | 84.2 | 57.1 | 83.3 | 62.5 |
| Week 12 | 100 | 92.7 | 97.0 | 96.7 | 81.1 | 89.5 | 64.3 | 83.3 | 62.5 |
| Week 16 | 100 | 90.9 | 97.0 | 96.7 | 83.8 | 78.9 | 57.1 | 66.7 | 62.5 |
| Week 20 | 100 | 85.5 | 93.9 | 96.7 | 89.2 | 84.2 | 71.4 | 66.7 | 75.0 |
| Week 24 | 100 | 81.8 | 97.0 | 93.3 | 83.8 | 84.2 | 64.3 | 83.3 | 62.5 |
| Week 28 | 93.3 | 89.1 | 97.0 | 93.3 | 86.5 | 84.2 | 71.4 | 66.7 | 62.5 |
| Week 32 | 100 | 85.5 | 93.9 | 93.3 | 89.2 | 78.9 | 71.4 | 66.7 | 50.0 |
| Week 36 | 100 | 81.8 | 90.9 | 93.3 | 86.5 | 78.9 | 71.4 | 66.7 | 37.5 |
| Week 40 | 100 | 83.6 | 87.9 | 86.7 | 86.5 | 78.9 | 71.4 | 66.7 | 50.0 |
| Week 44 | 100 | 81.8 | 87.9 | 86.7 | 83.8 | 78.9 | 71.4 | 66.7 | 50.0 |
| Week 48 | 100 | 78.2 | 87.9 | 86.7 | 89.2 | 68.4 | 71.4 | 66.7 | 62.5 |
Collected over From PS0011 Baseline and up to Safety-Follow Up (SFU) (up to Week 64). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Bimekizumab 64 mg Q4W (SS) | 0/15 (0%) | 1/15 (6.7%) | 10/15 (66.7%) |
| Bimekizumab 160 mg Q4W (SS) | 0/111 (0%) | 7/111 (6.3%) | 56/111 (50.5%) |
| Bimekizumab 320 mg Q4W (SS) | 2/91 (2.2%) | 7/91 (7.7%) | 51/91 (56%) |
| Event | Bimekizumab 64 mg Q4W (SS) | Bimekizumab 160 mg Q4W (SS) | Bimekizumab 320 mg Q4W (SS) |
|---|---|---|---|
| Non-cardiac chest painGeneral disorders | 1/15 | 0/111 | 0/91 |
| CataractEye disorders | 0/15 | 0/111 | 1/91 |
| Otitis externa bacterialInfections and infestations | 0/15 | 0/111 | 1/91 |
| Humerus fractureInjury, poisoning and procedural complications | 0/15 | 0/111 | 1/91 |
| Tibia fractureInjury, poisoning and procedural complications | 0/15 | 0/111 | 1/91 |
| Carpal tunnel syndromeNervous system disorders | 0/15 | 0/111 | 1/91 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/15 | 0/111 | 1/91 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 0/15 | 0/111 | 1/91 |
| Abortion inducedSurgical and medical procedures | 0/15 | 0/111 | 1/91 |
| Circulatory collapseVascular disorders | 0/15 | 0/111 | 1/91 |
| Event | Bimekizumab 64 mg Q4W (SS) | Bimekizumab 160 mg Q4W (SS) | Bimekizumab 320 mg Q4W (SS) |
|---|---|---|---|
| Oral candidiasisInfections and infestations | 1/15 | 13/111 | 15/91 |
| NasopharyngitisInfections and infestations | 2/15 | 15/111 | 11/91 |
| Urinary tract infectionInfections and infestations | 2/15 | 1/111 | 1/91 |
| PsoriasisSkin and subcutaneous tissue disorders | 2/15 | 5/111 | 5/91 |
| HypertensionVascular disorders | 2/15 | 8/111 | 4/91 |
| Upper respiratory tract infectionInfections and infestations | 1/15 | 10/111 | 9/91 |
| External ear inflammationEar and labyrinth disorders | 1/15 | 0/111 | 1/91 |
| DiarrhoeaGastrointestinal disorders | 1/15 | 0/111 | 1/91 |
| FlatulenceGastrointestinal disorders | 1/15 | 0/111 | 0/91 |
| Non-alcoholic fatty liverHepatobiliary disorders | 1/15 | 1/111 | 0/91 |
Baseline characteristics refer to the Safety Set (SS) which consisted of all participants who received at least 1 dose of the investigational medicinal product (IMP) in PS0011.
| Age, Categorical(Participants) | Bimekizumab 64 mg Q4W | Bimekizumab 160 mg Q4W | Bimekizumab 320 mg Q4W | Total Title |
|---|---|---|---|---|
| <=18 years | 0 | 1 | 2 | 3 |
| Between 18 and 65 years | 14 | 105 | 77 | 196 |
| >=65 years | 1 | 5 | 12 | 18 |
| Age, Continuous(years) | Bimekizumab 64 mg Q4W | Bimekizumab 160 mg Q4W | Bimekizumab 320 mg Q4W | Total Title |
|---|---|---|---|---|
| Mean | 44.5 ± 14.7 | 44.5 ± 12.8 | 43.5 ± 14.7 | 44.1 ± 13.7 |
| Sex: Female, Male(Participants) | Bimekizumab 64 mg Q4W | Bimekizumab 160 mg Q4W | Bimekizumab 320 mg Q4W | Total Title |
|---|---|---|---|---|
| Female | 6 | 40 | 31 | 77 |
| Male | 9 | 71 | 60 | 140 |
| Race/Ethnicity, Customized(Participants) | Bimekizumab 64 mg Q4W | Bimekizumab 160 mg Q4W | Bimekizumab 320 mg Q4W | Total Title |
|---|---|---|---|---|
| American Indian /Alaskan native | 0 | 1 | 1 | 2 |
| Asian | 1 | 11 | 6 | 18 |
| Black | 1 | 0 | 1 | 2 |
| White | 13 | 99 | 83 | 195 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2016 to primary completion in Sep 2018, 21 months.
Results were first posted in Oct 2021, 3 years 1 month after primary completion. A results delay was requested in Sep 2019.
Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's 21 months is above that.
Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bimekizumab